Overview of Sales, Earnings and Financial Position
Bayer Links
News
 |
Phase III study program on rivaroxaban in chronic indications After extensive discussions with the regulatory authorities in the U.S. and Europe, Bayer and Johnson & Johnson subsidiary Ortho-McNeil, Inc. have determined the final design of the phase III study program for the oral anticoagulant rivaroxaban in two chronic indications. » more |
| China is of central importance to Bayer At a ceremony before 500 guests, Bayer inaugurated the new production facilities of the Bayer MaterialScience subgroup in Shanghai. China is of central importance to Bayer in the Asia-Pacific region – both as a production base and for the company’s business strategy, explained Bayer AG Management Board Chairman Werner Wenning. » more |
 |
 |
Schering integration well on track Bayer is proceeding apace with the integration of Schering. In recent weeks, executive appointments in the future Bayer Schering Pharma AG, Germany* have been made through the third management level, and three further major decisions have now also been made following the registration of the domination and profit and loss transfer agreement in the commercial register. » more |
Further News:
Bayer divests holding in GE Bayer Silicones*
The names "Bayer Schering Pharma" or "Schering" as used in this publication always refer to Bayer Schering Pharma AG, Berlin, Germany, or its predecessor, Schering AG, Berlin, Germany, respectively.
Bookmark this page
E-mail this page
Advanced Search
